Home / Market News / $BIIB
benzinga Corporate Catalyst Impact 65/100 ● positive

JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300

Oct 12, 2026, 12:08 PM UTC · Primary ticker $BIIB

JP Morgan has upgraded Biogen's stock rating from Neutral to Overweight and increased its price target from $210 to $300. This analyst upgrade signals increased confidence in Biogen's future performance, which could lead to positive short-term stock movement.

JP Morgan analyst Chris Schott upgraded Biogen (BIIB) from Neutral to Overweight and raised its price target from $210 to $300. This move indicates a more optimistic outlook from a major investment bank regarding Biogen's prospects, likely driven by new data, pipeline developments, or market positioning. For traders, this presents a short-term opportunity for positive price momentum as the market reacts to the increased confidence. The long-term implications depend on whether Biogen can meet or exceed the expectations set by this new price target, with the key opportunity being potential capital appreciation if the company performs well.

$BIIB positive Analyst upgrade and price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.